ANI Pharmaceuticals, Inc. (ANIP)
73.09
+1.17
(+1.63%)
USD |
NASDAQ |
Sep 02, 16:00
73.09
0.00 (0.00%)
After-Hours: 17:53
ANI Pharmaceuticals Research and Development Expense (TTM) : 49.91M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 49.91M |
| March 31, 2026 | 51.70M |
| December 31, 2025 | 51.66M |
| September 30, 2025 | 56.05M |
| June 30, 2025 | 53.87M |
| March 31, 2025 | 44.63M |
| December 31, 2024 | 44.58M |
| September 30, 2024 | 37.80M |
| June 30, 2024 | 38.80M |
| March 31, 2024 | 38.87M |
| December 31, 2023 | 34.29M |
| September 30, 2023 | 29.64M |
| June 30, 2023 | 26.18M |
| March 31, 2023 | 22.97M |
| December 31, 2022 | 22.32M |
| September 30, 2022 | 20.24M |
| June 30, 2022 | 15.26M |
| March 31, 2022 | 14.42M |
| December 31, 2021 | 12.15M |
| September 30, 2021 | 15.68M |
| June 30, 2021 | 15.97M |
| March 31, 2021 | 19.32M |
| December 31, 2020 | 27.26M |
| September 30, 2020 | 31.78M |
| June 30, 2020 | 33.98M |
| Date | Value |
|---|---|
| March 31, 2020 | 33.08M |
| December 31, 2019 | 26.51M |
| September 30, 2019 | 18.80M |
| June 30, 2019 | 18.30M |
| March 31, 2019 | 17.66M |
| December 31, 2018 | 15.39M |
| September 30, 2018 | 14.56M |
| June 30, 2018 | 12.52M |
| March 31, 2018 | 9.554M |
| December 31, 2017 | 9.07M |
| September 30, 2017 | 6.554M |
| June 30, 2017 | 4.961M |
| March 31, 2017 | 3.558M |
| December 31, 2016 | 2.906M |
| September 30, 2016 | 3.432M |
| June 30, 2016 | 3.206M |
| March 31, 2016 | 3.437M |
| December 31, 2015 | 2.874M |
| September 30, 2015 | 2.781M |
| June 30, 2015 | 2.849M |
| March 31, 2015 | 2.705M |
| December 31, 2014 | 2.678M |
| September 30, 2014 | 2.634M |
| June 30, 2014 | 2.205M |
| March 31, 2014 | 1.792M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Viatris, Inc. | 995.00M |
| Liquidia Corp. | 54.95M |
| Elanco Animal Health, Inc. | 371.00M |
| Harmony Biosciences Holdings, Inc. | 220.87M |
| Corcept Therapeutics, Inc. | 253.86M |